Elsevier

Clinical Therapeutics

Volume 20, Issue 3, May–June 1998, Pages 424-437
Clinical Therapeutics

Clinical Studies
Fluticasone propionate 50 μg BID versus 100 μg BID in the treatment of children with persistent asthma

https://doi.org/10.1016/S0149-2918(98)80053-2Get rights and content

Abstract

The aim of this multicenter, double-masked study was to compare the efficacy and safety of two different doses of inhaled fluticasone propionate dry powder—50 μg and 100 μg—administered BID via a multidose powder inhaler with those of placebo in the treatment of children with persistent asthma. After a 2-week run-in period, 263 patients were randomized to treatment with twice-daily placebo (n = 92), fluticasone 50 μg (n = 85), or fluticasone 100 μg (n = 86) for 12 weeks. One hundred sixty-six (63%) patients were male, and 224 (85%) were white, with a mean age of 8 years. Two hundred twenty-one (84%) patients were atopic, and 167 (63%) had been asthmatic for 1 to 5 years. Baseline mean morning peak expiratory flow (PEF) values were 207 L/min, 199 L/min, and 194 L/min, and baseline percentages of predicted normal values were 86%, 80%, and 81% for the groups receiving placebo, fluticasone 50 μg, and fluticasone 100 μg, respectively. At the end of the first week of treatment, patients in both fluticasone groups had significantly greater improvements in morning PEF than did those receiving placebo. Patients experienced mean increases of 4 L/min, 22 L/min, and 26 L/min with placebo, fluticasone 50 μg, and fluticasone 100 μg, respectively. At the end point (the last evaluable visit), patients in both fluticasone groups continued to have significantly greater improvements in morning PEF than did patients receiving placebo. Patients experienced mean increases of 17 L/min, 50 L/min, and 57 L/min with placebo, fluticasone 50 μg, and fluticasone 100 μg, respectively. Changes in the percentage of predicted values by end point were 8%, 20%, and 26% with placebo, fluticasone 50 μg, and fluticasone 100 μg, respectively. The probability of remaining in the study, according to predefined withdrawal criteria, indicated a significant treatment difference in favor of fluticasone. Withdrawal criteria were met by 63%, 42%, and 29% of patients receiving placebo, fluticasone 50 μg, and fluticasone 100 μg, respectively. This study clearly demonstrates the superiority of fluticasone 50 and 100 μg BID over placebo in the treatment of persistent asthma in children.

References (20)

There are more references available in the full text version of this article.

Cited by (39)

  • The safety of long-term use of inhaled corticosteroids in patients with asthma: A systematic review and meta-analysis

    2022, Clinical Immunology
    Citation Excerpt :

    The P value of Begg's rank correlation test (STATA 12.0) was used to assess the presence of publication bias in included articles for each outcome. Of 17,234 trials recognized by the initial search, 331 were retrieved for more detailed assessment, and 86 trials [8–91,105–107] were included in the meta-analysis (Fig. 1). Baseline characteristics of trials included in the meta-analysis are shown in Table 1.

  • Individualized homeopathy in a group of Egyptian asthmatic children

    2012, Homeopathy
    Citation Excerpt :

    Several placebo-controlled trials among children 4–11 years of age compared fluticasone with placebo during a 12-week, double-blind period. After 12 weeks, the improvement in FEV1 for patients receiving 100 μg of fluticasone twice per day was 0.23L, 0.25L and 0.27L with little placebo effect.29–31 Our study showed a significant increase of 0.21L in FEV1(13%) after 6 months of treatment with homeopathic medicines.

  • The treatment of asthma in children: Inhaled corticosteroids

    2007, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    Again no significant difference was seen between any of the individual doses used in the study. The effect of 100 and 200 μg/d FP Diskhaler was compared with that of placebo among 263 children with asthma [54]. Both doses of FP led to significant improvements in PEF and asthma symptom score over 6 and 12 weeks, but no significant difference was seen between the effects of the two doses of FP in any other measured parameter.

  • Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: A randomized, double-blind, placebo-controlled study

    2006, Journal of Pediatrics
    Citation Excerpt :

    Overall FP systemic exposure was low and was not associated with changes in urine cortisol excretion from baseline. A similar lack of effect of FP on UC excretion was observed in other studies in children.4,15,21-28 Specifically, there was no correlation between FP systemic exposure and change in UC from baseline.

View all citing articles on Scopus
1

Members of the Fluticasone Propionate Study Group are listed in the Acknowledgments.

View full text